Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today
Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:1945

Ariad Pharmaceuticals, Inc. (ARIA) - Financial and Strategic SWOT Analysis Review

Ariad Pharmaceuticals, Inc. (ARIA) - Financial and Strategic SWOT Analysis Review

Double click on above image to view full picture

Zoom Out
Zoom In
Additional Information
Price $125.00
Meta Description Ariad Pharmaceuticals Inc (ARIAD) is a biopharmaceutical company discovering, developing and marketing small-molecule oncology therapies. The company is focused on developing small-molecule drugs that treat solid tumors and hematologic cancers. The compan
Publisher GlobalData
Date of Report Dec 3, 2013
Quick Overview
Summary

Ariad Pharmaceuticals Inc (ARIAD) is a biopharmaceutical company discovering, developing and marketing small-molecule oncology therapies. The company is focused on developing small-molecule drugs that treat solid tumors and hematologic cancers. The company’s only marketed product – ponatinib (brand name–Iclusig), is recently approved for the treatment of chronic myeloid leukemia (CML).

Ariad Pharmaceuticals, Inc. Key Recent Developments

Mar 04, 2013: Industry Leaders And Academic Researchers Come Together For Innovative Accelerating Cancer Cures Research Symposium
Feb 25, 2013: Ariad Pharma Reports Q4 2012 Results
Jan 07, 2013: Ariad To Establish Corporate And R&D Headquarters At Alexandria Center In Massachusetts, US
Nov 07, 2012: Ariad Pharma Reports Q3 2012 Results
Aug 02, 2012: Ariad Pharma Reports Q2 2012 ResultsGDPH61132FSA

This comprehensive SWOT profile of Ariad Pharmaceuticals, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Ariad Pharmaceuticals, Inc. - Key Facts 5
Ariad Pharmaceuticals, Inc. - Key Employees 6
Ariad Pharmaceuticals, Inc. - Key Employee Biographies 7
Ariad Pharmaceuticals, Inc. - Major Products and Services 9
Ariad Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data 10
Ariad Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10
Ariad Pharmaceuticals, Inc., Pipeline Products by Development Phase 11
Ariad Pharmaceuticals, Inc. - History 13
Ariad Pharmaceuticals, Inc. - Company Statement 15
Ariad Pharmaceuticals, Inc. - Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Section 2 – Company Analysis 21
Ariad Pharmaceuticals, Inc. - Business Description 21
Ariad Pharmaceuticals, Inc. - Corporate Strategy 22
Ariad Pharmaceuticals, Inc. - SWOT Analysis 23
SWOT Analysis - Overview 23
Ariad Pharmaceuticals, Inc. - Strengths 23
Strength - Collaboration with Merck 23
Strength - Intellectual Property 23
Strength - Orphan Drug Designation - ponatinib 23
Strength - Potential Ponatinib Revenue From Leukemia 24
Ariad Pharmaceuticals, Inc. - Weaknesses 24
Weakness - History of Operating Losses 24
Weakness - No Product Revenues 24
Ariad Pharmaceuticals, Inc. - Opportunities 24
Opportunity - Potential Market for Cancer Therapies 24
Opportunity - Robust Oncology Product Pipeline 25
Opportunity - Increase in Life Expectancy 25
Ariad Pharmaceuticals, Inc. - Threats 25
Threat - Tightening of FDA’s Regulatory Oversight 25
Threat - Uncertain R&D Outcomes 25
Threat - Competitive Pressures 26
Ariad Pharmaceuticals, Inc. - Key Competitors 27
Section 3 – Company Financial Ratios 28
Financial Ratios - Capital Market Ratios 28
Financial Ratios - Annual Ratios 28
Performance Chart 30
Financial Performance 30
Financial Ratios - Interim Ratios 31
Financial Ratios - Ratio Charts 32
Section 4 – Company’s Lifesciences Financial Deals and Alliances 33
Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 33
Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 34
Ariad Pharmaceuticals, Inc., Recent Deals Summary 35
Section 5 – Company’s Recent Developments 36
Ariad Pharmaceuticals, Inc., Recent Developments 36
Mar 04, 2013: Industry Leaders And Academic Researchers Come Together For Innovative Accelerating Cancer Cures Research Symposium 36
Feb 25, 2013: Ariad Pharma Reports Q4 2012 Results 36
Jan 07, 2013: Ariad To Establish Corporate And R&D Headquarters At Alexandria Center In Massachusetts, US 39
Nov 07, 2012: Ariad Pharma Reports Q3 2012 Results 39
Aug 02, 2012: Ariad Pharma Reports Q2 2012 Results 41
May 09, 2012: Ariad Reports Q1 2012 Results 42
Mar 26, 2012: ARIAD To Present Preclinical Data At American Association For Cancer Research Annual Meeting 43
Feb 28, 2012: Ariad Reports Q4 2011 Results 44
Jan 03, 2012: ARIAD Pharma To Trade On NASDAQ Global Select Market 46
Section 6 – Appendix 47
Methodology 47
Ratio Definitions 47
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Ariad Pharmaceuticals, Inc., Key Facts 5
Ariad Pharmaceuticals, Inc., Key Employees 6
Ariad Pharmaceuticals, Inc., Key Employee Biographies 7
Ariad Pharmaceuticals, Inc., Major Products and Services 9
Ariad Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area 10
Ariad Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage 11
Ariad Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase 12
Ariad Pharmaceuticals, Inc., History 13
Ariad Pharmaceuticals, Inc., Subsidiaries 20
Ariad Pharmaceuticals, Inc., Key Competitors 27
Ariad Pharmaceuticals, Inc., Ratios based on current share price 28
Ariad Pharmaceuticals, Inc., Annual Ratios 28
Ariad Pharmaceuticals, Inc., Interim Ratios 31
Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 33
Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 34
Ariad Pharmaceuticals, Inc., Recent Deals Summary 35
Currency Codes 47
Capital Market Ratios 47
Equity Ratios 48
Profitability Ratios 48
Cost Ratios 49
Liquidity Ratios 49
Leverage Ratios 50
Efficiency Ratios 50

List of Figures
Ariad Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10
Ariad Pharmaceuticals, Inc., Pipeline Products by Development Phase 11
Ariad Pharmaceuticals, Inc., Performance Chart (2007 - 2011) 30
Ariad Pharmaceuticals, Inc., Ratio Charts 32
Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 33
Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013 34




...